Analysis: GSK bolsters medicine chest with biotechnology buy – Reuters
By Dr. Matthew Watson
 AFP | Analysis: GSK bolsters medicine chest with biotechnology buy Reuters LONDON (Reuters) - GlaxoSmithKline chief executive Andrew Witty has an eye for a bargain. Despite paying a 99 percent premium for Human Genome Sciences, he is still getting the biotechnology company for less than half what it was worth 14 months ago. GSK bolsters medicine chest with biotechnology buyReuters UK GSK clinches $3B deal to buy Human GenomeNational Post Glaxo to Buy Human GenomeWall Street Journal |
Source:
http://news.google.com/news?q=biotechnology&output=rss
Uncategorized
Comments Off on Analysis: GSK bolsters medicine chest with biotechnology buy – Reuters |
July 22nd, 2012
This author published 5852 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research